| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. | Chief Patient Officer | Common Stock | 1.8K | $16.1K | $8.93 | Jun 18, 2025 | Direct |
| Provention Bio, Inc. | Chief Commercial Officer | Common Stock | 0 | $24.32 | Feb 10, 2023 | Direct | |
| Provention Bio, Inc. | Chief Commercial Officer | Option to Purchase Common Stock | 0 | Apr 27, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | Jun 18, 2025 | 0 | $0 | 3 | Jun 23, 2025 | Chief Patient Officer |
| PRVB | Provention Bio, Inc. | Apr 27, 2023 | 5 | $0 | 4 | Apr 27, 2023 | Chief Commercial Officer |
| PRVB | Provention Bio, Inc. | Feb 10, 2023 | 1 | -$45K | 4 | Feb 14, 2023 | Chief Commercial Officer |
| PRVB | Provention Bio, Inc. | Jan 10, 2023 | 1 | $0 | 4 | Jan 11, 2023 | Chief Commercial Officer |
| PRVB | Provention Bio, Inc. | Dec 8, 2022 | 2 | $0 | 4 | Dec 9, 2022 | Chief Commercial Officer |
| PRVB | Provention Bio, Inc. | Jan 18, 2022 | 1 | $0 | 4 | Jan 20, 2022 | Chief Commercial Officer |
| PRVB | Provention Bio, Inc. | May 12, 2021 | 1 | $0 | 4 | May 14, 2021 | Chief Commercial Officer |